Last reviewed · How we verify

Cerebrolysin infusion — Competitive Intelligence Brief

Cerebrolysin infusion (Cerebrolysin infusion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuropeptide mixture. Area: Neurology.

marketed Neuropeptide mixture Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Cerebrolysin infusion (Cerebrolysin infusion) — Clinical Institute of the Brain, Russia. Cerebrolysin is a standardized peptide and amino acid mixture derived from porcine brain that promotes neuroprotection and neuroplasticity through multiple mechanisms including neurotrophic factor activity and metabolic support.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cerebrolysin infusion TARGET Cerebrolysin infusion Clinical Institute of the Brain, Russia marketed Neuropeptide mixture

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuropeptide mixture class)

  1. Clinical Institute of the Brain, Russia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cerebrolysin infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/cerebrolysin-infusion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: